Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats

Brain Research

Volumn 971, Issue 1, 2003, Pages 18-30

  Oh, Justin D ^a   Geller, Alfred I ^b   Zhang, Guo Rong ^b   Chase, Thomas N ^c  

^a CENTRAL MICHIGAN UNIVERSITY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

6 Hydroxydopamine lesion; AMPA receptor; Basal ganglia; Chronic levodopa administration; Herpes Simplex Vector type 1 vector; Phosphorylation

Indexed keywords

2,6 DIAMINO N [[1 (1 OXOTRIDECYL) 2 PIPERIDYL]METHYL]HEXANAMIDE; AMPA RECEPTOR; LEVODOPA; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RECEPTOR SUBUNIT; SERINE; VIRUS VECTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; MALE; MICROINJECTION; MOTOR ACTIVITY; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PKCBETA2 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STRIATE CORTEX;

EID: 0037414411     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02348-5     Document Type: Article

References (86)

1. Banke T.G., Bowie D., Lee H.K., Huganir R.L., Schousboe A., Traynelis S.F. Control of GluR1 AMPA receptor function by cAMP-Dependent Protein Kinase. J. Neurosci. 20:2000;89-102.
2. 2+/calmodulin-dependent protein kinase II regulatory phosphorylation site in the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate-type glutamate receptor. J. Biol. Chem. 272:(52):1997;327-32730.
3. Bédard P.J., Blanchet P.J., Lévesque D., Soghomonian J.J., Grondin R., Morissette M., Goulet M., Calon F., Falardeau P., Gomez-Mancilla B., Doucet J.P., Robertson G.S., DiPaolo T. Pathophysiology of L-dopa-induced dyskinesias. Mov. Dis. 14:(Suppl. 1):1999;4-8.
4. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharm. Exp. Theor. 290:(3):1999;1034-1040.
5. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 21:1997.
6. Borges K., Dingledine R. AMPA receptors: molecular and functional diversity. Prog. Brain Res. 116:1998;153-170.
7. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. Eur. J. Neurosci. 10:1998;2887-2895.
8. Calon F., Hadj Tahar A., Blanchet P.J., Morissette M., Grondin R., Goulet M., Doucet J.P., Robertson G.S., Nestler E., Di Paolo T., Bédard P.J. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 23:(10):2000;S92-S100.
9. 2+/calmodulin-dependent protein kinase II activity and AMPA GluR1 subunit immunoreactivity. Eur. J. Neurosci. 10:1998;2669-2676.
10. Carvalho A.L., Duarte C.B., Carvalho A.P. Regulation of AMPA receptors by phosphorylation. Neurochem. Res. 35:(9/10):2000;1245-1255.
11. Carvalho A.L., Kameyama K., Huganir R.L. Characterization of phosphorylation sites on the glutamate receptor 4 subunit of the AMPA receptors. J. Neurosci. 19:1999;4748-4754.
12. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:1998;2694-2706.
13. Chase T.N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson' disease. Drugs. 55:1998;1-9.
14. Chase T.N., Konitsiotis S., Oh J.D. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv. Neurol. 86:2001;355-360.
15. Chase T.N., Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 47:(4):2000;S122-S129.
16. Chase T.N., Oh J.D., Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology. 51:1998;S30-S35.
17. Chase T.N., Oh J.D., Konitsiosis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247:2000;S36-S42.
18. Daw M.I., Chittajallu R., Bortolotto Z.A., Dev K.K., Duprat F., Henley J.M., Collingridge G.L., Isaac J.T. PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron. 28:(3):2000;873-886.
19. 2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc. Natl. Acad. Sci. USA. 96:1999;3269-3274.
20. Dev K.K., Nishimune A., Henley J.M., Nakanishi S. The protein kinase C alpha binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits. Neruopharmacology. 38:1999;635-644.
21. Dunah A.W., Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21:(15):2001;5546-5558.
22. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of parkinson's disease. Mol. Pharm. 57:2000;342-352.
23. During M.J., Naegele J.R., O'Malley K.L., Geller A.I. Long term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science. 266:1994;1399-1403.
24. Emson P.C., Shohman S., Feler C., Buss T., Price J. The use of a retroviral vector to identify foetal striatal neurons transplanted into the adult striatum. Exp. Brain Res. 79:1990;427-430.
25. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 5:1994;2586-2588.
26. Fraefel C., Song S., Lim F., Lang P., Yu L., Wang Y., Wild P., Geller A.I. Helper virus-free transfer of HSV-1 plasmid vectors into neural cells. J. Virol. 70:1996;7190-7197.
27. Geller A.I. Genetic analysis of the role of protein kinase C signaling pathways in behaviors by direct gene transfer with HSV-1 vectors. Rev. Neurosci. 18:1999;1-13.
28. Geller A.I., Yu L., Wang Y.M., Fraefel C. Helper virus-free simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Exp. Neurol. 144:1997;98-102.
29. Graybiel A.M., Aosakin T., Flaherty A.W., Kimura M. The basal ganglia and adaptive motor control. Science. 265:1994;1826-1831.
30. Hayashi Y., Ishida A., Katagiri H., Mishina M., Fujisawa H., Manage T., Takahashi T. Calcium- and calmodulin-dependent phosphorylation of AMPA type glutame receptor subunits by endogenous protein kinases in the post-synaptic density. Mol. Brain Res. 46:1997;338-342.
31. Hayashi Y., Shi S.H., Esteban J.A., Piccini A., Poncer J.C., Malinow R. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science. 287:(5461):2000;2262-2267.
32. Hsu K.S., Ho W.C., Huang C.C., Tsai J.J. Transient removal of extracellular Mg(2+) elicits persistent suppression of LTP at hippocampal CA1 synapses via PKC activation. J. Neurophys. 84:(3):2000;1279-1288.
33. Hsu K.S., Huang C.C. Protein kinase C inhibitors block generation of anoxia-induced long-term potentiation. Neuroreport. 9:1998;3525-3529.
34. Hurtig H.I. Problems with current pharmacologic treatment of Parkinson's disease. Exp. Neurol. 144:1997;10-16.
35. Khan S.M., Smith T.S., Bennett J.P. Effects of single and multiple treatments with L-dihydroxyphenylalanine (l-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions. J. Neurosci. Res. 55:1999;71-79.
36. Kohr G., Seeburg P.H. Subtype-specific regulation of recombinant NMDA receptor-channel by protein tyrosine kinases of the src family. J. Physiol. (Lond.). 492:1996;445-452.
37. Kong Y., Yang T., Geller A.I. An efficient in vivo recombination cloning procedure for modifying and combining HSV-1 cosmids. J. Virol. Methods. 80:(2):1999;129-136.
38. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54:(8):2000;1589-1595.
39. Lee H.K., Barbarosie M., Kameyama K., Bear M.F., Huganir R.L. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature. 405:(6789):2000;955-959.
40. Lim F., Hartley D., Starr P., Lang P., Song S., Yu L., Wang Y., Geller A.I. Generation of high-titer defective HSV-1 vectors using IE 2 deletion mutant and quantitative study of expression in cultured cortical cells. BioTechniques. 20:1996;460-470.
41. Lu W.Y., Xiong Z.G., Lei S., Orser B.A., Dudek E., Browning M.D., Macdonald J.F. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat. Neurosci. 2:1999;331-338.
42. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15:(1):2002;120-132.
43. Mammen A.L., Kameyama K., Roche K.W., Huganir R.L. Phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II. J. Biol. Chem. 272:(51):1997;32528-32533.
44. Maniatus T., Fritsch E.F., Sambrook J. Molecular Cloning. 1982;Cold Spring Harbor Laboratory, New York.
45. Marin C., Jimenez A., Bonastre M., Chase T.N., Tolosa E. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response complications in parkinsonian rats. Synapse. 36:2000;267-274.
46. Marin C., Jiménez A., Bonastre M., Vila M., Agid Y., Hirsch E.C., Tolosa E. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse. 42:(1):2001;40-47.
47. Marin C., Jimenez A., Vila M. Effects of the AMPA glutamate receptor antagonist LY293558 on the motor response alterations induced by chronic administration of levodopa in parkinsonian rats. Mov. Disord. 13:1998;281.
48. Marin C., Papa S.M., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK801 prevents levodopa-induced motor response alteration in parkinsonian rats. Brain Res. 736:1996;202-205.
49. Matsuyama S., Namgung U., Routtenburg A. Long-term potentiation persistence greater in C57BL/6 than DBA/2 mice: predicted on basis of protein kinase C levels and learning performance. Brain Res. 763:1997;127-130.
50. Menegoz M., Lau L.F., Herve D., Huganir R.L., Girault J.A. Tyrosine phosphorylation on NMDA receptor in rat striatum: effect of 6-OHDA dopamine lesions. Neuroreport. 7:1995;125-128.
51. Metman L.V., Blanchet P.J., Mouradian M.M., Chase T.N. Dextromethorphan and levodopa combination therapy in parkinsons's patients with response fluctuations. Mov. Disord. 11:1996;184.
52. Metman L.V., Dotto P.D., Blanchet P.J., Munckhof P.V.D., Chase T.N. Blockade of glutamergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14:1998;75-82.
53. Metman L.V., Locatelli E.R., Bravi D., Mouradian M.M., Chase T.N. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology. 50:1998;574.
54. Nishizaki T., Matsumura T. The aniracetam metabolite 2-pyrrolidinone induces a long-term enhancement in AMPA receptor responses via a CaMKII pathway. Mol. Brain Res. 98:(1/2):2002;130-134.
55. Oh J.D., Dotto P.D., Chase T.N. Protein kinase A inhibitor attenuates motor response alterations in the hemi-parkinsonian rat. Neurosci. Lett. 228:1997;5-8.
56. Oh J.D., Russell D., Vaughan C.L., Chase T.N. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and levodopa administration. Brain Res. 813:1998;150-159.
57. Oh J.D., Vaughan C.L., Chase T.N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res. 813:1999;433-442.
58. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:1995;13-18.
59. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
60. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
61. Prickett K.S., Amberg D.C., Hopp T.P. A calcium-dependent antibody for identification and purification of recombinant proteins. BioTechniques. 7:1989;580-589.
62. Ramakers G.M., Mcnamara R.K., Lenox R.H., Graan P.N.E.D. Differential changes in the phosphorylation of the protein substrates myristoylated alanine-rich C kinase substrate and growth-associated protein-43/B-50 following Schaffer collateral long-term potentiation and long-term depression. J. Neurochem. 73:1999;2175-2183.
63. Ramakers G.M., Pasinelli P., Hens J.J., Gispen W.H., Graan P.N.E.D. Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre- and postsynaptic substrates. Prog. Neuropsychopharmacol. Biol. Psychiatry. 21:1997;455-486.
64. Roche K.W., Obrien R.J., Mammen A.L., Bernhardt J., Huganir R.L. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron. 16:1996;1179-1188.
65. Sacktor T.C., Osten P., Valsamis H., Jiang X., Naik M.U., Sublette E. Persistent activation of isoform of protein kinase C in the maintenance of long-term potentiation. Proc. Natl. Acad. Sci. USA. 90:1993;8342-8346.
66. Smith Y., Shink E., Sidibe M. Neuronal circuitry and synaptic connectivity of the basal ganglia. Neurosurg. Clin. North Am. 9:1998;203.
67. Snyder G.L., Allen P.B., Fienberg A.A., Valle C.G., Huganir R.L., Nairn A.C., Greengard P. Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J. Neurosci. 20:(12):2000;4480-4488.
68. Snyder G.L., Yan Z., Galdi S., Allen P.B., Feinberg A.A., Bibb J.A., Huganir R.L., Nairn A.C., Greengard P. A D1-receptor/PKA/DARPP-32/PPI pathway regulates ampa receptor phosphorylation and conductance in the neostriatum. Br. J. Pharmacol. 133:2001;268.
69. Song S., Wang Y., Bak S.Y., During M.J., Bryan J., Ashe O., Ullrey D.B., Trask L.E., Grant F.D., O'Malley K.L., Reidel H., Goldstein D.S., Neve K.A., Lahoste G.T., Marshall J.F., Haycock J.W., Neve R.L., Geller A.I. Modulation of rat rotational behavior by direct gene transfer of constitutively active protein kinase C into nigrostriatal neurons. J. Neurosci. 18:1998;4119-4132.
70. Stefani A., Chen Q., Flores-Hernandez J., Jiao Y., Reiner A., Surmeier D.J. Physiological and molecular properties of AMPA/kainate receptors expressed by striatal medium spiny neurons. Dev. Neurosci. 20:1998;242-252.
71. Steketee J.D., Rowe L.A., Chandler L.T. The effects of acute and repeated cocaine injections on protein kinase C activity and isoform levels in dopaminergic brain regions. Neuropharmacology. 37:1998;339-347.
72. Suen P., Wu K., Xu J.I., Lin S.Y., Levine E.S., Black I.B. NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Mol. Brain Res. 59:1998;215-228.
73. Sullivan E.T. 2,6-Diamino-N-([1-{1-oxotridecyl)-2-piperidinyl]-methyl)hexaneamide (NPC-15437): a novel inhibitor of protein kinase C interacting at the regulatory domain. Mol. Pharm. 41:1992;38-44.
74. Sun M., Shang G., Yang T., Yu L., Geller A.I. Improved titers for helper virus-free HSV-1 plasmid vectors by both an optimized protocol and addition of non-infectious HSV related particle (PREPs) to the packaging procedure. Hum. Gene Ther. 10:1999;2005-2011.
75. Suzuki T., Okumura-Noji K. NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem. Biophys. Res. Commun. 216:1995;582-588.
76. Tanaka C., Nishizuka Y. The protein kinase C family for neuronal signaling. Annu. Rev. Neurosci. 17:1994;551-567.
77. Tang J., Yang T., Ghosh H.P., Geller A.I. Helper virus-free HSV-1 vectors packaged both in the presence of VSV G protein and in the absence of HSV-1 glycoprotein B support gene transfer into neurons in the rat striatum. J. Neurovirol. 7:(6):2001;548-555.
78. Terwilliger R.Z., Beitner-Johnson D., Sevarino K.A., Crain S.M., Nestler E.J. A general role for adaptations in G proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res. 548:1991;100-110.
79. Verhagen Metman L., Del Dotto P., Blanchet P.J., Van Den Munckhof P., Chase T.N. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14:(1-3):1998;75-82.
80. Vila M., Marin C., Ruberg M., Jimenez A., Raisman-Vozari R., Agid Y., Tolosa E., Hirsch E.C. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. J. Neurochem. 73:(1):1999;344-352.
81. Vinade L., Dosemeci A. Regulation of the phosphorylation state of the AMPA receptor GluR1 subunit in the postsynaptic density. Cell. Mol. Neurobiol. 20:(4):2000;451-463.
82. Wang X., Zhang G.R., Sun M., Geller A.I. General strategy for constructing large HSV-1 plasmid vectors that co-express multiple genes. BioTechniques. 31:(1):2001;204-212.
83. Wang X., Zhang G.R., Yang T., Zhang W., Geller A.I. Fifty-one kilobase HSV-1 plasmid vector can be packaged using a helper virus-free system and supports expression in the rat brain. BioTechniques. 28:(1):2000;102-107.
84. Westin J.E., Andersson M., Lundblad M., Cenci M.A. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci. 14:(7):2001;1171-1176.
85. Yang T., Zhang G.R., Zhang W., Sun M., Wang X., Geller A.I. Enhanced reporter gene expression in the rat brain from helper virus-free HSV-1 vectors packaged in the presence of specific mutated HSV-1 proteins that affect the virion. Mol. Brain Res. 90:(1):2001;1-16.
86. Zhang G.R., Wang X., Yang T., Sun M., Zhang W., Wang Y., Geller A.I. A tyrosine hydroxylase-neurofilament chimeric promoter enhances long-term expression in rat forebrain neurons from helper virus-free HSV-1 vectors. Mol. Brain Res. 84:(1/2):2000;17-31.